US20010023274A1 - Methods and apparatus for the production of amorphous polymer suspensions - Google Patents
Methods and apparatus for the production of amorphous polymer suspensions Download PDFInfo
- Publication number
- US20010023274A1 US20010023274A1 US09/843,556 US84355601A US2001023274A1 US 20010023274 A1 US20010023274 A1 US 20010023274A1 US 84355601 A US84355601 A US 84355601A US 2001023274 A1 US2001023274 A1 US 2001023274A1
- Authority
- US
- United States
- Prior art keywords
- suspension
- polymer
- polymer particles
- amorphous
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims abstract description 61
- 229920006125 amorphous polymer Polymers 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000002245 particle Substances 0.000 claims abstract description 133
- 229920000642 polymer Polymers 0.000 claims abstract description 96
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims abstract description 54
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims abstract description 52
- 238000010438 heat treatment Methods 0.000 claims abstract description 19
- 238000002844 melting Methods 0.000 claims abstract description 17
- 230000008018 melting Effects 0.000 claims abstract description 17
- 238000001816 cooling Methods 0.000 claims abstract description 15
- 238000004581 coalescence Methods 0.000 claims abstract description 10
- 229920006126 semicrystalline polymer Polymers 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- ALRHLSYJTWAHJZ-UHFFFAOYSA-M 3-hydroxypropionate Chemical compound OCCC([O-])=O ALRHLSYJTWAHJZ-UHFFFAOYSA-M 0.000 claims description 2
- PHOJOSOUIAQEDH-UHFFFAOYSA-N 5-hydroxypentanoic acid Chemical compound OCCCCC(O)=O PHOJOSOUIAQEDH-UHFFFAOYSA-N 0.000 claims description 2
- IWHLYPDWHHPVAA-UHFFFAOYSA-M 6-hydroxyhexanoate Chemical compound OCCCCCC([O-])=O IWHLYPDWHHPVAA-UHFFFAOYSA-M 0.000 claims description 2
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 238000005112 continuous flow technique Methods 0.000 claims 1
- 238000007669 thermal treatment Methods 0.000 abstract description 32
- 238000002425 crystallisation Methods 0.000 abstract description 14
- 230000008025 crystallization Effects 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 14
- 239000007900 aqueous suspension Substances 0.000 abstract description 7
- 239000000047 product Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000178 monomer Substances 0.000 description 5
- 230000006911 nucleation Effects 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000232299 Ralstonia Species 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000005102 attenuated total reflection Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229940096992 potassium oleate Drugs 0.000 description 2
- MLICVSDCCDDWMD-KVVVOXFISA-M potassium;(z)-octadec-9-enoate Chemical compound [K+].CCCCCCCC\C=C/CCCCCCCC([O-])=O MLICVSDCCDDWMD-KVVVOXFISA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- NDPLAKGOSZHTPH-UHFFFAOYSA-N 3-hydroxyoctanoic acid Chemical compound CCCCCC(O)CC(O)=O NDPLAKGOSZHTPH-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000252867 Cupriavidus metallidurans Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001572351 Lycaena dorcas Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/88—Post-polymerisation treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Definitions
- the present invention is generally in the field of suspensions of polymer particles, and more particularly to methods for producing suspensions of amorphous polymer particles, especially of polyhydroxyalkanoate polymers.
- PHAs Polyhydroxyalkanoates
- a particularly useful form of PHAs is a suspension including polymer particles suspended in water, wherein a majority of the particles are in an amorphous, i.e. noncrystalline, state. These suspensions have application in ambient temperature film formation, since the glass transition temperature (T g ) of PHAs is generally less than 5° C.
- Amorphous PHA suspensions (which also are referred to as amorphous latexes or emulsions) have been found to be particularly useful in, for example, architectural paints (GB 2,291,648), cathode-ray tube metallization lacquers (PCT/GB95/02761), and coatings for paper (U.S. Pat. No. 5,451,456), cellulose or nonwoven objects (PCT/GB96/00284), and foods (PCT/NL95/00222).
- Amorphous PHA particles can remain noncrystalline almost indefinitely, even when cooled 100° C. or more below the crystalline melting temperature, provided that the particles are sufficiently small and behave independently from each other, as they do in aqueous suspension (Horowitz, et al., J. Am. Chem. Soc. 116:2695-702 (1994)). They remain amorphous even if the temperature is maintained well above T g , conditions at which the bulk polymer would crystallize rapidly. This unexpected stability in the amorphous state has been explained based on nucleation kinetics (de Koning & Lemstra, Polymer 33:3292-94 (1992)).
- the theoretical model predicts that the observed rate of crystallization for an ensemble of polymer particles varies inversely with the particle volume, i.e. with the third power of particle diameter.
- the half-time for the crystallization process accordingly can be expressed as (log e 2)/Iv, where I is the nucleation rate constant and v is the volume of an individual particle.
- I the nucleation rate constant
- v the volume of an individual particle.
- amorphous particles are quite stable in a water suspension, when the suspension is applied to a surface and allowed to dry, the particles coalesce to form a coherent or semi-coherent crystalline film having desirable functional properties.
- PHA suspensions for forming biodegradable, hydrolyzable, or thermolyzable films, it has generally proven difficult to prepare these materials on a commercial scale.
- amorphous PHA suspensions have been prepared from crystalline polymer by solvent emulsification routes.
- PHAs poly-3-hydroxybutyrate (PHB), poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV or BIOPOLTM), and poly-3-hydroxyoctanoate (PHO) have been prepared as amorphous particles by dissolving the polymer in chloroform, emulsifying the polymer solution with a solution of aqueous surfactant, and heating the emulsion to remove the organic solvent (U.S. Pat. No. 5,599,891; Horowitz & Sanders, Polymer 35:5079-84 (1994)).
- Suspensions of amorphous PHO particles also have been prepared by dispersing an acetone solution of the polymer in water, and then removing the acetone by distillation (Marchessault, et al., Can. J. Microbiol. 41:13842 (1995)).
- a similar approach is described in PCT/GB96/00305 by Liddell, et al., in which a suspension of amorphous PHBV is made by mixing a solution of polymer in propanediol at high temperature with water and surfactant, and then removing the organic solvent by diafiltration.
- PCT/GB95/01925 by Liddell, et al. also discloses a method for producing a “PHBV latex” by heating a slurry of crystalline PHBV powder in water and detergent under pressure for ten minutes at a temperature above the melting temperature of the polymer. It is not disclosed whether the particles remained in the amorphous state upon cooling, or what the final particle size of the slurry is.
- This method has the disadvantage that the particle size of the final product is dictated by the size of the powder starting material, which is at least 20-50 ⁇ m. Particles of this size crystallize rapidly upon cooling (see Table 1 above), giving even an initially amorphous suspension a useful shelf-life of less than four days. The duration of the thermal treatment in this case also causes significant further agglomeration of the particles. Suspensions containing large particles are generally unsuitable for film forming applications.
- PHAs are generally preferable to purify PHAs using aqueous (i.e. organic solvent-free) methods, particularly in commercial scale processes, in which the polymer remains in a microparticulate state and the non-PHA biomass is solubilized through mechanical, chemical, and/or enzymatic treatments.
- the PHA particles then are separated from the solubilized material using centrifugation, filtration, floatation, or other convenient methods.
- EP 0 145 233 discloses aqueous methods for purifying a microbiological 3-hydroxybutyrate polymer wherein the cells are heat-treated at above 80° C. and then digested with enzymes, surfactants, and/or hydrogen peroxide.
- the undesirable crystallization that occurs during aqueous harvesting may be minimized by the use of various stabilizers, such as alkyl ethoxylates, acrylic graft copolymers, and some ionic surfactants, as disclosed, for example, in PCT/GB96/00284 and PCT/US96/1986.
- these approach can be costly and has several disadvantages.
- the success of the stabilizers in preventing crystallization tends to be polymer composition-dependent, with the faster crystallizing PHAs giving the poorest results.
- Suspensions of PHB and PHBV copolymers for example, invariably contain some crystalline particles when processed using the stabilizers.
- the most effective agents are steric stabilizers (for example, the acrylic graft copolymer Hypermer CG6, available from ICI Surfactants) which remain tightly associated with the polymer particles and have a detrimental effect on subsequent film formation.
- Methods and apparati are provided for producing a suspension of predominately amorphous polymer particles, wherein the method includes thermally treating a suspension that includes crystalline or semi-crystalline polymer particles.
- the thermal treatment includes (a) heating a suspension of polymer particles of an appropriate size to a temperature effective to cause the polymer to become amorphous, and then (b) cooling the suspension of amorphous polymer particles below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles.
- the method can be conducted in a continuous, semi-continuous or batch mode thermal treatment, and can be performed at non-atmospheric pressure conditions depending upon the polymer and suspending medium selected.
- the method and apparati are effective for use with a variety of polymers having suitable crystallization parameters, although polyhydroxyalkanoate (PHA) polymers are preferred, particularly in an aqueous suspension medium.
- PHA polyhydroxyalkanoate
- the polymer particles subjected to treatment preferably are of a size of less than 5 ⁇ m, or more preferably less than 1.5 ⁇ m, in diameter.
- Stable amorphous polymer suspensions made using these methods and apparati also are provided.
- the polymer of these suspensions preferably is between about 80 and 100% amorphous, and preferably is present in the suspension medium at a concentration of between about 0.1 to 50% wt/wt, and more preferably between about 5 and 40% wt/wt.
- the amorphous polymer suspension preferably is suitable for use in film formation at ambient temperatures.
- FIG. 1 is a process flow diagram of a preferred embodiment of the apparatus for thermal treatment of the suspension of crystalline polymer particles.
- a suspension of highly amorphous polymer particles can be produced by thermally treating a suspension that includes crystalline or semi-crystalline polymer particles, without a significant increase in particle size, provided that the duration of thermal treatment is properly minimized.
- the polymer particles preferably are present in the suspension at a concentration between about 0.1 and 50% wt/wt, and more preferably between about 5 and 40% wt/wt. both before and after thermal treatment.
- PHAs polyhydroxyalkanoates
- Representative examples of other polymers which can be used in the methods, compositions, and apparati described herein include polymers such as polyolefins, polyimides, polyamides, and polyesters.
- the stability of the amorphous particles will depend upon many factors, including the particle size, nucleation kinetics, purity, and presence of surfactants and colloidal stabilizers.
- the PHAs can be derived from biological systems including bacteria and genetically engineered plant crops. In bacterial systems, the PHAs are accumulated intracellularly as granular inclusion bodies. PHA also can be produced in genetically engineered plant crops. Methods for recovering PHAs from plant biomass are described, for example in PCT WO 97/15681, PCT WO 97/07239, and PCT WO 97/07229. The methods described herein similarly are useful with a variety of PHAs, regardless of source organism or comonomer composition.
- PHAs include poly-3-hydroxybutyrate (PHB), poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV, marketed as BIOPOLTM by Monsanto), poly-3-hydroxybutyrate-co-4-hydroxybutyratepoly-3-hydroxypropionate, poly-3-hydroxybutyrate-co-3-hydroxypropionate, poly-4-hydroxybutyrate, poly-3-hydroxybutyrate-co-3-hydroxyhexanoate, poly-3-hydroxybutyrate-co-3-hydroxyoctanoate, poly-5-hydroxyvalerate, and poly-6-hydroxyhexanoate.
- PHB poly-3-hydroxybutyrate
- PHBV poly-3-hydroxybutyrate-co-3-hydroxyvalerate
- BIOPOLTM BIOPOLTM by Monsanto
- poly-3-hydroxybutyrate-co-4-hydroxybutyratepoly-3-hydroxypropionate poly-3-hydroxybutyrate-co-3-hydroxypropionate
- poly-4-hydroxybutyrate poly-3-hydroxybutyrate-
- the polymer in the product suspension preferably is between about 80 and 100% amorphous.
- the amorphous polymer suspension preferably is suitable for use in film formation at ambient temperatures, and preferably is stable.
- stable means that the polymer particles remain amorphous for a commercially useful period of time.
- the suspension should remain stable at ambient conditions for at least several days, and preferably several weeks or more, following manufacture, shipping, and storage, so that the suspension can be used when desired, particularly when used in film-forming processes.
- the particle size of the crystalline or partly crystalline polymer slurry feed is an important consideration in the methods described herein.
- PHA powders from aqueous isolation processes are crystalline with a particle size of at least 20-50 ⁇ m, which if subjected to the thermal treatment processes described herein would yield amorphous particles that crystallize too rapidly for practical use.
- a particle size of 5 ⁇ m, with a high degree of crystallinity is typical (D. M. Horowitz, Ph.D. Thesis, University of Cambridge, UK, 1994). Therefore, the particle size frequently must be reduced before thermal treatment is undertaken.
- Treatment of the crystalline slurry through a homogenizer, colloid mill, bead mill, or Microfluidizer is a suitable means to reduce the particle size to the desired range.
- a treatment of one to four passes through a Microfluidizer gives a suspension of crystalline microparticles about 1 ⁇ m median in size, which is suitable for use in the methods described herein.
- a surfactant, dispersant, or emulsifying agent may be added during the course of the aqueous isolation of the polymer particles, which has the effect of maintaining a smaller particle size throughout the process.
- the polymer is a PHA
- the polymer particles subjected to treatment are of a size of less than 5 ⁇ m, or more preferably less than 1.5 ⁇ m in diameter. Smaller particles have much longer observed lifetimes in the amorphous state (see Table 1) and can be undercooted 100° C. or more below T m without causing observable crystallization. However, for some slow nucleating materials larger particle sizes may be satisfactory and yield stable amorphous particles.
- the suspension medium is preferably water, although it can be an aqueous solution with at least about 50% (by weight) water with the balance including one or more water-miscible organic solvents, such as alcohols, ketones, acetone, and DMSO.
- the suspension can include one or more additives, such as surfactants, dispersants, emulsifiers, soaps, or detergents, any of which can be added before, during, or after thermal treatment. Although satisfactory results can also be obtained without such additives, surfactants may be useful to reduce any tendency of the particles to coalesce, aggregate, or adhere to the vessel during the thermal treatment.
- suitable surfactants include potassium oleate, and BRIJTM 721 (ICI, United Kingdom).
- Preferred amounts of surfactant are between about 0.1 and 10% (by weight of surfactant/weight of polymer), for example, about 3.4%.
- Any surfactant should be chosen such that its surface activity and solubility are maintained at the peak treatment temperature.
- the use of polyether-containing agents, including many nonionic surfactants and block- or graft-copolymeric stabilizers may need to be avoided in cases where the cloud point of the agent is below the melting temperature of the crystalline polymer.
- Surfactants also should be chosen to be compatible with the intended end use. For example, for most film-forming applications, it is desirable to avoid introducing any mineral residues, which would increase the water sensitivity of the film.
- the thermal treatment method includes (a) providing a suspension comprising crystalline or semi-crystalline polymer particles in a suspending medium; (b) heating the suspension to a temperature effective to cause the polymer to become amorphous; and (c) cooling the suspension below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles.
- Successful thermal treatments typically must be conducted at a temperature near, at, or above the melting temperature (T m ) of the crystalline polymer particles.
- T m melting temperature
- the term “near” in reference to the T m means the T m ⁇ 10° C., and preferably within about 2 to 5° C. of the T m .
- the thermal treatment temperature generally has no upper limit, although higher temperatures may trigger polymer degradation, and/or require the use of higher pressure process equipment in order to conduct the thermal treatment without boiling the suspension media. Accordingly, the preferred treatment temperature is generally between about 0 and 25° C. above the T m of the crystalline polymer.
- the T m of the polymer will be in excess of the normal boiling point of the suspending medium.
- the melting temperature for PHB is around 180° C.
- commercial PHBV copolymers typically melt between about 140 and 175° C., temperatures which well exceed the normal boiling point of water.
- the thermal treatment process should be performed so as to prevent boiling and evaporation of the water, or other suspension medium, from the suspension. In a preferred embodiment, this effect can conveniently be achieved by performing the process in a closed or pressure-regulated system.
- the duration of the thermal treatment should be no longer than necessary to convert the particles from the crystalline to the amorphous state; a few seconds near or above the melting temperature were found to be sufficient. Longer heating times are associated with increased coalescence of the particles, and ultimately phase separation of the polymer as a separate molten layer. It is also therefore desirable that the heating and cooling ramps to which the polymer suspension is subjected be as steep as practical.
- the thermal treatment can be conducted in a continuous, batch, or semi-batch process.
- a suspension of crystalline or semi-crystalline polymer particles is subjected to a continuous-flow thermal process which yields a suspension of amorphous particles.
- the treatment is performed in a batch mode using a closed pressure system.
- a polymer suspension of appropriate particle size can be heated in a sealable, pressure-rated tube, autoclave or other similar vessel, fitted with a stirring apparatus. The apparatus is then heated, for example, using an oil bath, steam, or other appropriate means. After the required minimum time of treatment, the apparatus is cooled and the product suspension is discharged.
- fractions can be removed, for example, by decantion, filtration, or centrifugation using standard process equipment.
- a preferred embodiment of the method is conducted in continuous-flow thermal process.
- the polymer suspension is pumped continuously or semi-continuously through a liquid conduit, wherein the suspension is subjected to a suitably high temperature for a brief interval.
- the conduit typically is operated under pressure to prevent boiling of the suspension medium.
- the apparatus for producing an amorphous polymer suspension includes (a) a pump suitable for pumping a suspension comprising crystalline or semi-crystalline polymer particles in a suspending medium; (b) a first heat exchanger having an inlet in fluid connection with the discharge of the pump and having an outlet, wherein the first heat exchanger is suitable for heating the suspension to a temperature effective to cause the polymer to become amorphous as the suspension flows between the inlet and the to the outlet; and (c) a second heat exchanger having an inlet in fluid connection with the outlet of the first heat exchanger, wherein the second heat exchanger is suitable for cooling the suspension below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles.
- FIG. 1 A preferred embodiment of a continuous-flow, pressurized thermal treatment apparatus is shown in FIG. 1.
- the thermal treatment apparatus 10 includes pump 12 ; liquid conduit 14 , which includes at least one heated zone 16 (i.e. a zone that is capable of being heated), i.e. the apparatus's first heat exchanger; and a pressure regulating or pressure-relief valve 18 .
- the preferred apparatus also includes suspension heat exchanger 20 , which efficiently transfers heat from the amorphous polymer particle (product) suspension to the crystalline polymer particle (feed) suspension.
- the apparatus optionally can include one or more auxiliary cooling devices (not shown) downstream from the heating zone, as it may be preferable to cool the discharge from the heated zone using an external cooling medium in some processes.
- the suspension heat exchanger 20 and/or the auxiliary cooling device function as the apparatus's second heat exchanger.
- thermal treatment apparatus 10 has a single suspension heat exchanger 20 , it will be readily apparent to those of skill in the art that the apparatus can be modified to use multiple heat exchangers for this purpose.
- suspension heat exchanger 20 can be eliminated, depending upon the process design conditions and process equipment selected, so long as the heating and cooling functions of the apparatus are served. Standard heat exchanger equipment can be used for heated zone 16 , suspension heat exchanger 20 , and any auxiliary cooling devices.
- thermal treatment apparatus 10 is operated as follows.
- a suspension of crystalline or partly crystalline polymer particles is fed by means of a pump 12 into a high-pressure loop which includes liquid conduit 14 , wherein the thermal treatment occurs.
- the feed may be at any temperature, provided the suspending medium remains liquid.
- pressure is maintained by means of pressure regulating valve 18 , which terminates the loop and discharges the amorphous product at a temperature and pressure at which the suspension medium will not boil.
- the pressure regulating valve is set to maintain an internal pressure which is greater than or equal to the vapor pressure of the suspension medium at the maximum temperature of treatment, in order to prevent boiling of the polymer suspension.
- the pump 12 obviously must be capable of generating positive flow at the set pressure of pressure-relief valve 18 .
- the apparatus optionally may be equipped with pressure and temperature monitoring devices at various points in the apparatus, and/or gas bladders to give more uniform flow and pressure behavior.
- the pressure regulating valve may be omitted.
- the feed flows through one side or channel of suspension heat exchanger 20 and then into heated zone 16 , where a temperature is near, at, or above the melting temperature of the crystalline polymer is induced in the suspension.
- the heat may be supplied, for example, as steam, gas or electric heating, either directly or via a transfer medium.
- the polymer suspension may be pumped through a heat exchanger, metal tube, flow-through vessel, or other device having favorable thermal conductivity. In all cases, the goal is to ensure rapid and efficient transfer of heat into the polymer suspension, bringing the polymer particles to a temperature near, at, or above the crystalline melting temperature.
- the heated suspension of amorphous polymer particles then flows from heated zone 16 and through the second channel of suspension heat exchanger 20 , thereby pre-heating the feed suspension before entering heated zone 16 so as to minimize the heating capacity required of the heated zone 16 and/or to decrease the residence time in heated zone 16 .
- the suspension heat exchanger 20 also cools the product suspension discharged from heated zone 16 , preferably to a temperature low enough to prevent boiling of the suspension upon discharge from pressure-relief valve 18 .
- compositions, methods and apparati described herein are further described by the following non-limiting examples.
- Particle size was measured by laser light scattering using a Coulter LS130 particle analyzer.
- Crystallinity index was measured using FTIR by the method described in Bloembergen, et al., Macromolecules, 19:2865-70 (1986), except that the determination was made on an aqueous suspension using an attenuated total reflection (ATR) sample device (Nicolet Instrument Corp.).
- ATR attenuated total reflection
- Amorphous particles showed characteristic IR bands at 1185 and 1303 cm ⁇ 1
- crystalline particles showed characteristic bands at 1228, 1280, and 1288 cm ⁇ 1 .
- Percent crystallinity index was estimated using standards, which were prepared by combining known amounts of fully amorphous and fully crystallized particles in water suspension.
- the fully amorphous particles were prepared as described in Horowitz et al. J. Am. Chem. Soc. 116:2695-702 (1994), while the fully crystallized particles were derived from spray-dried PHA powder.
- a crystallinity index of 100% thus represents the maximum crystallinity which the polymer is normally capable of achieving. For PHB, this corresponds to an X-ray crystallinity of approximately 70%.
- Cells of Ralstonia eutrophus NCIMB 40124 were fermented to high density on a mixture of glucose and valeric acid under conditions of phosphorus limitation.
- the cells contained 68% PHA (cell dry weight basis) which was a PHBV copolymer with a monomer ratio 92:8 HB/HV.
- the PHA was recovered by an aqueous process as follows.
- the cells were washed by diafiltration with distilled water, microfluidized twice at 15,000 psi and then digested with industrial protease (Alcalase, 1 mL/L, Novo Nordisk) in the presence of 0.5% (wt/vol) sodium dodecylsulfate (SDS) and 0.25% (wt/vol) Hypermer CG-6 (ICI Surfactants) for 1 hr at 50° C. (pH 9).
- the resulting PHA suspension was washed by diafiltration (U.S. Filter Membralox ceramic element with a 0.1 ⁇ m nominal cutoff) with 2 vol. of water containing 0.5% (wt/vol) SDS and 0.25% (wt/vol) Hypermer CG-6.
- the suspension was treated with hydrogen peroxide, 3% wt/vol, for 3 hr in the presence of diethylenetriaminepentaacetic acid (DTPA, 100 mg/L), at 80° C.
- DTPA diethylenetriaminepentaacetic acid
- the pH was maintained at 7 using ammonium hydroxide.
- the product was diafiltered as above with 6 vol. water containing 0.5% (wt/vol) SDS and 0.25% (wt/vol) Hypermer CG-6 followed by 6 vol. pure water.
- the particles were collected by centrifugation and resuspended in water at a concentration of 13% wt/wt.
- This PHA suspension which had a median particle size of 3.9 ⁇ m and a crystallinity index of 100%, was used as the starting material in the process of producing a suspension of amorphous polymeric particles.
- the PHA suspension then was processed four times through a Microfluidizer M110EH (Microfluidics International, Newton, Mass.) at an operating pressure of 15,000 psi.
- the resulting suspension had a crystallinity index of 100% and a median particle size of 0.50 ⁇ m.
- the melting temperature of the crystalline polymer was determined to be 169° C.
- the thermal treatment was repeated using a suspension of crystalline PHA in water at 30% (wt/wt) solids, rather than 13% (wt/wt).
- the resulting product again was a suspension including amorphous PHA particles.
- Cells of Ralstonia eutrophus NCIMB 40124 were fermented to high density on a mixture of glucose and valeric acid under conditions of phosphorus limitation.
- the cells contained 32% PHA (cell dry weight basis) which was a PHBV copolymer with a monomer ratio 75:25 HB/HV.
- the PHA was isolated as in Example 1, except that following peroxide treatment, the PHA was isolated by centrifugation and resuspension in water to give a polymer slurry of 6% solids (wt/wt). At this stage, the PHA had a crystallinity index of approximately 70%.
- the slurry was then processed four times at 20,000 psi through a Microfluidizer M110EH to reduce the particle size and then immersed for 5 min. in a sealed tube in a 200° C. oil bath.
- the resulting product was a suspension of amorphous PHA (0% crystallinity index by FTIR) with a median particle size of 0.73 ⁇ m.
- a continuous flow apparatus as illustrated in FIG. 1 was used to form a suspension of amorphous polymer particles.
- the apparatus included an electronic diaphragm metering pump (Pulsatron E series, 250 psi rated, maximum flow rate 0.79 L/hr), a heat exchanger (inlet 3 ⁇ 8′′ O.D. ⁇ 12′′ stainless pipe; outlet 1 ⁇ 8′′ O.D. ⁇ 12′′ copper pipe), a heated zone (1 ⁇ 8′′ O.D. ⁇ fraction (1/16) ⁇
- the apparatus also was equipped with a pressure gauge and two thermocouple-type electronic thermometers.
- the oil bath was pre-heated to 175° C. and the apparatus was operated on a pure water feed stream for 15 min to purge air bubbles and approach thermal equilibrium. Fluid pressure was sufficient to prevent boiling of the water.
- the feed was changed to a PHA suspension (PHB-co-8%HV from Example 1 above, 13% wt/wt solids, ca. 0.5 ⁇ m median particle size, 100% crystallinity index, supplemented with 1% wt/vol potassium oleate).
- a flow rate of 16.5 mL/min was achieved at a pressure of 220-230 psi, which was sufficient to prevent boiling of the suspension. At this flow rate, the residence time of the suspension within the heated zone was approximately nine seconds.
- the temperature of the suspension leaving the heated zone was measured at 176° C., while the suspension leaving the outlet of the heat exchanger had a temperature of 66° C.
- the product suspension contained 13% (wt/wt) solids with 0% crystallinity index by FTIR.
- the optical microscope showed a submicron suspension of spherical particles.
- Example 3 The procedures described in Example 3 above were repeated using a suspension including crystalline PHB particles (7.5% wt./wt. solids, 0.61 ⁇ m median particle size, crystallinity index 50%), obtained from fermentation of Ralstonia eutropha on glucose.
- the heating bath of the continuous flow apparatus was maintained at 197° C.
- the suspension has a temperature of 180° C. leaving the heated zone, while the suspension leaving the outlet of the heat exchanger had a temperature of 61° C.
- the discharged product included amorphous PHB particles (0.83 ⁇ m median particle size, 0% crystallinity index).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biological Depolymerization Polymers (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
- Priority is claimed to U.S. provisional application Serial No. 60/088,565, filed Jun. 9, 1998.
- The present invention is generally in the field of suspensions of polymer particles, and more particularly to methods for producing suspensions of amorphous polymer particles, especially of polyhydroxyalkanoate polymers.
- Polyhydroxyalkanoates (PHAs) are useful biodegradable thermoplastics obtained from microbes or plants or synthesized chemically. Although typically biological in origin, PHAs may be processed like conventional plastics to produce coatings, films, and molded objects. A particularly useful form of PHAs is a suspension including polymer particles suspended in water, wherein a majority of the particles are in an amorphous, i.e. noncrystalline, state. These suspensions have application in ambient temperature film formation, since the glass transition temperature (Tg) of PHAs is generally less than 5° C. Amorphous PHA suspensions (which also are referred to as amorphous latexes or emulsions) have been found to be particularly useful in, for example, architectural paints (GB 2,291,648), cathode-ray tube metallization lacquers (PCT/GB95/02761), and coatings for paper (U.S. Pat. No. 5,451,456), cellulose or nonwoven objects (PCT/GB96/00284), and foods (PCT/NL95/00222).
- Amorphous PHA particles can remain noncrystalline almost indefinitely, even when cooled 100° C. or more below the crystalline melting temperature, provided that the particles are sufficiently small and behave independently from each other, as they do in aqueous suspension (Horowitz, et al.,J. Am. Chem. Soc. 116:2695-702 (1994)). They remain amorphous even if the temperature is maintained well above Tg, conditions at which the bulk polymer would crystallize rapidly. This unexpected stability in the amorphous state has been explained based on nucleation kinetics (de Koning & Lemstra, Polymer 33:3292-94 (1992)). The theoretical model predicts that the observed rate of crystallization for an ensemble of polymer particles varies inversely with the particle volume, i.e. with the third power of particle diameter. The half-time for the crystallization process accordingly can be expressed as (loge 2)/Iv, where I is the nucleation rate constant and v is the volume of an individual particle. Using known nucleation rate constant data (Organ & Barham, J. Mater. Sci., 26:1368-74 (1991)), the half-times for crystallization of suspensions of various amorphous PHA particle sizes for poly-3-hydroxybutyrate (PHB) and poly-3-hydroxybutyrate-co-7%-hydroxyvalerate (PHBV) (BIOPOL™) at 30° C. have been calculated and are shown in Table 1 below.
TABLE 1 Predicted Half-times for Crystallization of Suspensions of Amorphous PHA Particles Particle Size PHB PHBV 100 μm 9 min 44 min 20 μm 18 hours 92 hours 5.0 μm 49 days 245 days 1.0 μm 17 years 84 years 0.2 μm 2099 years 10494 years - Although amorphous particles are quite stable in a water suspension, when the suspension is applied to a surface and allowed to dry, the particles coalesce to form a coherent or semi-coherent crystalline film having desirable functional properties. Despite the usefulness of such PHA suspensions for forming biodegradable, hydrolyzable, or thermolyzable films, it has generally proven difficult to prepare these materials on a commercial scale.
- In the laboratory, amorphous PHA suspensions have been prepared from crystalline polymer by solvent emulsification routes. For example, the PHAs poly-3-hydroxybutyrate (PHB), poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV or BIOPOL™), and poly-3-hydroxyoctanoate (PHO) have been prepared as amorphous particles by dissolving the polymer in chloroform, emulsifying the polymer solution with a solution of aqueous surfactant, and heating the emulsion to remove the organic solvent (U.S. Pat. No. 5,599,891; Horowitz & Sanders,Polymer 35:5079-84 (1994)). Suspensions of amorphous PHO particles also have been prepared by dispersing an acetone solution of the polymer in water, and then removing the acetone by distillation (Marchessault, et al., Can. J. Microbiol. 41:13842 (1995)). A similar approach is described in PCT/GB96/00305 by Liddell, et al., in which a suspension of amorphous PHBV is made by mixing a solution of polymer in propanediol at high temperature with water and surfactant, and then removing the organic solvent by diafiltration. The disadvantage, however, of all of the foregoing methods is that the particle suspension is highly diluted, necessitating extensive concentration at the end of the process and resulting in a low throughput of material. In addition, an organic solvent is used and removed in the process, which necessitates the use of costly solvent recovery and purification equipment when conducted on a commercial scale.
- PCT/GB95/01925 by Liddell, et al. also discloses a method for producing a “PHBV latex” by heating a slurry of crystalline PHBV powder in water and detergent under pressure for ten minutes at a temperature above the melting temperature of the polymer. It is not disclosed whether the particles remained in the amorphous state upon cooling, or what the final particle size of the slurry is. This method, however, has the disadvantage that the particle size of the final product is dictated by the size of the powder starting material, which is at least 20-50 μm. Particles of this size crystallize rapidly upon cooling (see Table 1 above), giving even an initially amorphous suspension a useful shelf-life of less than four days. The duration of the thermal treatment in this case also causes significant further agglomeration of the particles. Suspensions containing large particles are generally unsuitable for film forming applications.
- It is generally preferable to purify PHAs using aqueous (i.e. organic solvent-free) methods, particularly in commercial scale processes, in which the polymer remains in a microparticulate state and the non-PHA biomass is solubilized through mechanical, chemical, and/or enzymatic treatments. The PHA particles then are separated from the solubilized material using centrifugation, filtration, floatation, or other convenient methods. For example, EP 0 145 233 discloses aqueous methods for purifying a microbiological 3-hydroxybutyrate polymer wherein the cells are heat-treated at above 80° C. and then digested with enzymes, surfactants, and/or hydrogen peroxide.
- Although the PHA granules contained in microbial cells are completely amorphous (Barnard & Sanders,J. Biol. Chem. 264:3286-91 (1989)), the polymer suspensions obtained through aqueous harvesting methods usually have a substantial percentage of crystalline particles, which accumulate throughout the course of processing (D. M. Horowitz, Ph.D. Thesis, University of Cambridge, UK, 1994). The undesirable crystallization of the polymer particles is most pronounced with those PHAs having relatively fast crystallization kinetics, such as PHB and PHBV copolymers having 20 mol % or less 3-hydroxyvalerate content. The exact mechanism of crystallization is not fully understood; however, it is believed that certain conditions of temperature, shear, and/or contact among polymer particles or between particles and nucleating surfaces all promote crystallization at a rate well beyond that predicted by simple homogeneous nucleation kinetics. It has been found experimentally that the presence of even a modest fraction of crystalline polymer particles in the suspension results in an inferior, porous, and irregular film under ambient temperature conditions, since particle coalescence does not occur.
- The undesirable crystallization that occurs during aqueous harvesting may be minimized by the use of various stabilizers, such as alkyl ethoxylates, acrylic graft copolymers, and some ionic surfactants, as disclosed, for example, in PCT/GB96/00284 and PCT/US96/1986. However, this approach can be costly and has several disadvantages. The success of the stabilizers in preventing crystallization tends to be polymer composition-dependent, with the faster crystallizing PHAs giving the poorest results. Suspensions of PHB and PHBV copolymers, for example, invariably contain some crystalline particles when processed using the stabilizers. Moreover, the most effective agents are steric stabilizers (for example, the acrylic graft copolymer Hypermer CG6, available from ICI Surfactants) which remain tightly associated with the polymer particles and have a detrimental effect on subsequent film formation.
- It is therefore an object of the present invention to provide methods and apparati for producing a suspension of predominately amorphous polymer particles.
- It is another object of the present invention to provide aqueous suspensions of amorphous PHA particles having a size suitable for forming PHA coatings, films, and molded objects.
- Methods and apparati are provided for producing a suspension of predominately amorphous polymer particles, wherein the method includes thermally treating a suspension that includes crystalline or semi-crystalline polymer particles. The thermal treatment includes (a) heating a suspension of polymer particles of an appropriate size to a temperature effective to cause the polymer to become amorphous, and then (b) cooling the suspension of amorphous polymer particles below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles. The method can be conducted in a continuous, semi-continuous or batch mode thermal treatment, and can be performed at non-atmospheric pressure conditions depending upon the polymer and suspending medium selected.
- The method and apparati are effective for use with a variety of polymers having suitable crystallization parameters, although polyhydroxyalkanoate (PHA) polymers are preferred, particularly in an aqueous suspension medium. For PHA polymers, the polymer particles subjected to treatment preferably are of a size of less than 5 μm, or more preferably less than 1.5 μm, in diameter.
- Stable amorphous polymer suspensions made using these methods and apparati also are provided. The polymer of these suspensions preferably is between about 80 and 100% amorphous, and preferably is present in the suspension medium at a concentration of between about 0.1 to 50% wt/wt, and more preferably between about 5 and 40% wt/wt. The amorphous polymer suspension preferably is suitable for use in film formation at ambient temperatures.
- FIG. 1 is a process flow diagram of a preferred embodiment of the apparatus for thermal treatment of the suspension of crystalline polymer particles.
- It was discovered that a suspension of highly amorphous polymer particles can be produced by thermally treating a suspension that includes crystalline or semi-crystalline polymer particles, without a significant increase in particle size, provided that the duration of thermal treatment is properly minimized.
- I. Suspension of Polymer Particles
- The polymer particles preferably are present in the suspension at a concentration between about 0.1 and 50% wt/wt, and more preferably between about 5 and 40% wt/wt. both before and after thermal treatment.
- Polymers
- The methods and apparati described herein are useful with a range of polymeric materials having suitable crystallization parameters, although polyhydroxyalkanoates (PHAs) are especially preferred. Representative examples of other polymers which can be used in the methods, compositions, and apparati described herein include polymers such as polyolefins, polyimides, polyamides, and polyesters. The stability of the amorphous particles will depend upon many factors, including the particle size, nucleation kinetics, purity, and presence of surfactants and colloidal stabilizers.
- The PHAs can be derived from biological systems including bacteria and genetically engineered plant crops. In bacterial systems, the PHAs are accumulated intracellularly as granular inclusion bodies. PHA also can be produced in genetically engineered plant crops. Methods for recovering PHAs from plant biomass are described, for example in PCT WO 97/15681, PCT WO 97/07239, and PCT WO 97/07229. The methods described herein similarly are useful with a variety of PHAs, regardless of source organism or comonomer composition. Representative PHAs include poly-3-hydroxybutyrate (PHB), poly-3-hydroxybutyrate-co-3-hydroxyvalerate (PHBV, marketed as BIOPOL™ by Monsanto), poly-3-hydroxybutyrate-co-4-hydroxybutyratepoly-3-hydroxypropionate, poly-3-hydroxybutyrate-co-3-hydroxypropionate, poly-4-hydroxybutyrate, poly-3-hydroxybutyrate-co-3-hydroxyhexanoate, poly-3-hydroxybutyrate-co-3-hydroxyoctanoate, poly-5-hydroxyvalerate, and poly-6-hydroxyhexanoate.
- The polymer in the product suspension preferably is between about 80 and 100% amorphous. The amorphous polymer suspension preferably is suitable for use in film formation at ambient temperatures, and preferably is stable. As used herein, the term “stable” means that the polymer particles remain amorphous for a commercially useful period of time. For example, the suspension should remain stable at ambient conditions for at least several days, and preferably several weeks or more, following manufacture, shipping, and storage, so that the suspension can be used when desired, particularly when used in film-forming processes.
- Particle Size
- The particle size of the crystalline or partly crystalline polymer slurry feed is an important consideration in the methods described herein. Generally, PHA powders from aqueous isolation processes are crystalline with a particle size of at least 20-50 μm, which if subjected to the thermal treatment processes described herein would yield amorphous particles that crystallize too rapidly for practical use. Prior to drying, but at the end of an aqueous isolation process, a particle size of 5 μm, with a high degree of crystallinity, is typical (D. M. Horowitz, Ph.D. Thesis, University of Cambridge, UK, 1994). Therefore, the particle size frequently must be reduced before thermal treatment is undertaken.
- Treatment of the crystalline slurry through a homogenizer, colloid mill, bead mill, or Microfluidizer is a suitable means to reduce the particle size to the desired range. For example, a treatment of one to four passes through a Microfluidizer gives a suspension of crystalline microparticles about 1 μm median in size, which is suitable for use in the methods described herein. As an alternative or adjunct to particle size reduction, a surfactant, dispersant, or emulsifying agent may be added during the course of the aqueous isolation of the polymer particles, which has the effect of maintaining a smaller particle size throughout the process.
- When the polymer is a PHA, it is preferred that the polymer particles subjected to treatment are of a size of less than 5 μm, or more preferably less than 1.5 μm in diameter. Smaller particles have much longer observed lifetimes in the amorphous state (see Table 1) and can be undercooted 100° C. or more below Tm without causing observable crystallization. However, for some slow nucleating materials larger particle sizes may be satisfactory and yield stable amorphous particles.
- Suspension Media
- The suspension medium is preferably water, although it can be an aqueous solution with at least about 50% (by weight) water with the balance including one or more water-miscible organic solvents, such as alcohols, ketones, acetone, and DMSO. The suspension can include one or more additives, such as surfactants, dispersants, emulsifiers, soaps, or detergents, any of which can be added before, during, or after thermal treatment. Although satisfactory results can also be obtained without such additives, surfactants may be useful to reduce any tendency of the particles to coalesce, aggregate, or adhere to the vessel during the thermal treatment. Representative examples of suitable surfactants include potassium oleate, and BRIJ™ 721 (ICI, United Kingdom). Preferred amounts of surfactant are between about 0.1 and 10% (by weight of surfactant/weight of polymer), for example, about 3.4%.
- Any surfactant should be chosen such that its surface activity and solubility are maintained at the peak treatment temperature. For example, the use of polyether-containing agents, including many nonionic surfactants and block- or graft-copolymeric stabilizers, may need to be avoided in cases where the cloud point of the agent is below the melting temperature of the crystalline polymer. Surfactants also should be chosen to be compatible with the intended end use. For example, for most film-forming applications, it is desirable to avoid introducing any mineral residues, which would increase the water sensitivity of the film.
- II. Thermal Treatment Process
- The thermal treatment method includes (a) providing a suspension comprising crystalline or semi-crystalline polymer particles in a suspending medium; (b) heating the suspension to a temperature effective to cause the polymer to become amorphous; and (c) cooling the suspension below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles.
- Successful thermal treatments typically must be conducted at a temperature near, at, or above the melting temperature (Tm) of the crystalline polymer particles. As used herein, the term “near” in reference to the Tm means the Tm±10° C., and preferably within about 2 to 5° C. of the Tm. The thermal treatment temperature generally has no upper limit, although higher temperatures may trigger polymer degradation, and/or require the use of higher pressure process equipment in order to conduct the thermal treatment without boiling the suspension media. Accordingly, the preferred treatment temperature is generally between about 0 and 25° C. above the Tm of the crystalline polymer.
- In many cases, the Tm of the polymer will be in excess of the normal boiling point of the suspending medium. For example, the melting temperature for PHB is around 180° C., and commercial PHBV copolymers typically melt between about 140 and 175° C., temperatures which well exceed the normal boiling point of water. Thus, the thermal treatment process should be performed so as to prevent boiling and evaporation of the water, or other suspension medium, from the suspension. In a preferred embodiment, this effect can conveniently be achieved by performing the process in a closed or pressure-regulated system.
- The duration of the thermal treatment should be no longer than necessary to convert the particles from the crystalline to the amorphous state; a few seconds near or above the melting temperature were found to be sufficient. Longer heating times are associated with increased coalescence of the particles, and ultimately phase separation of the polymer as a separate molten layer. It is also therefore desirable that the heating and cooling ramps to which the polymer suspension is subjected be as steep as practical.
- The thermal treatment can be conducted in a continuous, batch, or semi-batch process. In a preferred embodiment, a suspension of crystalline or semi-crystalline polymer particles is subjected to a continuous-flow thermal process which yields a suspension of amorphous particles. In one embodiment, the treatment is performed in a batch mode using a closed pressure system. For example, a polymer suspension of appropriate particle size can be heated in a sealable, pressure-rated tube, autoclave or other similar vessel, fitted with a stirring apparatus. The apparatus is then heated, for example, using an oil bath, steam, or other appropriate means. After the required minimum time of treatment, the apparatus is cooled and the product suspension is discharged.
- Stirring or agitating the suspension during thermal treatment is generally desirable to prevent settling and to ensure uniform and rapid heating. However, significant shearing of the amorphous particles should be avoided, as it may promote coalescence, aggregation, and/or recrystallization of the material.
- In some cases, it may be desirable to remove a fraction of coalesced, larger particles, before or after thermal treatment. Such fractions can be removed, for example, by decantion, filtration, or centrifugation using standard process equipment.
- III. Thermal Treatment Apparatus
- As described above, a preferred embodiment of the method is conducted in continuous-flow thermal process. For example, the polymer suspension is pumped continuously or semi-continuously through a liquid conduit, wherein the suspension is subjected to a suitably high temperature for a brief interval. The conduit typically is operated under pressure to prevent boiling of the suspension medium.
- The Apparatus
- In a preferred embodiment, the apparatus for producing an amorphous polymer suspension includes (a) a pump suitable for pumping a suspension comprising crystalline or semi-crystalline polymer particles in a suspending medium; (b) a first heat exchanger having an inlet in fluid connection with the discharge of the pump and having an outlet, wherein the first heat exchanger is suitable for heating the suspension to a temperature effective to cause the polymer to become amorphous as the suspension flows between the inlet and the to the outlet; and (c) a second heat exchanger having an inlet in fluid connection with the outlet of the first heat exchanger, wherein the second heat exchanger is suitable for cooling the suspension below the melting point of the polymer at a rate effective to prevent substantial coalescence of the polymer particles.
- A preferred embodiment of a continuous-flow, pressurized thermal treatment apparatus is shown in FIG. 1. The
thermal treatment apparatus 10 includespump 12;liquid conduit 14, which includes at least one heated zone 16 (i.e. a zone that is capable of being heated), i.e. the apparatus's first heat exchanger; and a pressure regulating or pressure-relief valve 18. The preferred apparatus also includessuspension heat exchanger 20, which efficiently transfers heat from the amorphous polymer particle (product) suspension to the crystalline polymer particle (feed) suspension. The apparatus optionally can include one or more auxiliary cooling devices (not shown) downstream from the heating zone, as it may be preferable to cool the discharge from the heated zone using an external cooling medium in some processes. Thesuspension heat exchanger 20 and/or the auxiliary cooling device function as the apparatus's second heat exchanger. Althoughthermal treatment apparatus 10 has a singlesuspension heat exchanger 20, it will be readily apparent to those of skill in the art that the apparatus can be modified to use multiple heat exchangers for this purpose. Alternatively,suspension heat exchanger 20 can be eliminated, depending upon the process design conditions and process equipment selected, so long as the heating and cooling functions of the apparatus are served. Standard heat exchanger equipment can be used forheated zone 16,suspension heat exchanger 20, and any auxiliary cooling devices. - Operation of the Apparatus
- In a preferred embodiment,
thermal treatment apparatus 10 is operated as follows. A suspension of crystalline or partly crystalline polymer particles is fed by means of apump 12 into a high-pressure loop which includesliquid conduit 14, wherein the thermal treatment occurs. The feed may be at any temperature, provided the suspending medium remains liquid. Within the pressurized section of the loop, pressure is maintained by means ofpressure regulating valve 18, which terminates the loop and discharges the amorphous product at a temperature and pressure at which the suspension medium will not boil. The pressure regulating valve is set to maintain an internal pressure which is greater than or equal to the vapor pressure of the suspension medium at the maximum temperature of treatment, in order to prevent boiling of the polymer suspension. Thepump 12 obviously must be capable of generating positive flow at the set pressure of pressure-relief valve 18. - The apparatus optionally may be equipped with pressure and temperature monitoring devices at various points in the apparatus, and/or gas bladders to give more uniform flow and pressure behavior. In cases where the maximum treatment temperature does not exceed the boiling point of the suspending medium, the pressure regulating valve may be omitted.
- From
pump 12, the feed flows through one side or channel ofsuspension heat exchanger 20 and then intoheated zone 16, where a temperature is near, at, or above the melting temperature of the crystalline polymer is induced in the suspension. The heat may be supplied, for example, as steam, gas or electric heating, either directly or via a transfer medium. For example, the polymer suspension may be pumped through a heat exchanger, metal tube, flow-through vessel, or other device having favorable thermal conductivity. In all cases, the goal is to ensure rapid and efficient transfer of heat into the polymer suspension, bringing the polymer particles to a temperature near, at, or above the crystalline melting temperature. The heated suspension of amorphous polymer particles then flows fromheated zone 16 and through the second channel ofsuspension heat exchanger 20, thereby pre-heating the feed suspension before enteringheated zone 16 so as to minimize the heating capacity required of theheated zone 16 and/or to decrease the residence time inheated zone 16. Thesuspension heat exchanger 20 also cools the product suspension discharged fromheated zone 16, preferably to a temperature low enough to prevent boiling of the suspension upon discharge from pressure-relief valve 18. - The compositions, methods and apparati described herein are further described by the following non-limiting examples.
- Particle size was measured by laser light scattering using a Coulter LS130 particle analyzer. Crystallinity index was measured using FTIR by the method described in Bloembergen, et al.,Macromolecules, 19:2865-70 (1986), except that the determination was made on an aqueous suspension using an attenuated total reflection (ATR) sample device (Nicolet Instrument Corp.). Amorphous particles showed characteristic IR bands at 1185 and 1303 cm−1, while crystalline particles showed characteristic bands at 1228, 1280, and 1288 cm−1. Percent crystallinity index was estimated using standards, which were prepared by combining known amounts of fully amorphous and fully crystallized particles in water suspension. The fully amorphous particles were prepared as described in Horowitz et al. J. Am. Chem. Soc. 116:2695-702 (1994), while the fully crystallized particles were derived from spray-dried PHA powder. A crystallinity index of 100% thus represents the maximum crystallinity which the polymer is normally capable of achieving. For PHB, this corresponds to an X-ray crystallinity of approximately 70%.
- Cells ofRalstonia eutrophus NCIMB 40124 were fermented to high density on a mixture of glucose and valeric acid under conditions of phosphorus limitation. The cells contained 68% PHA (cell dry weight basis) which was a PHBV copolymer with a monomer ratio 92:8 HB/HV. The PHA was recovered by an aqueous process as follows. The cells were washed by diafiltration with distilled water, microfluidized twice at 15,000 psi and then digested with industrial protease (Alcalase, 1 mL/L, Novo Nordisk) in the presence of 0.5% (wt/vol) sodium dodecylsulfate (SDS) and 0.25% (wt/vol) Hypermer CG-6 (ICI Surfactants) for 1 hr at 50° C. (pH 9). The resulting PHA suspension was washed by diafiltration (U.S. Filter Membralox ceramic element with a 0.1 μm nominal cutoff) with 2 vol. of water containing 0.5% (wt/vol) SDS and 0.25% (wt/vol) Hypermer CG-6. After diafiltration the suspension was treated with hydrogen peroxide, 3% wt/vol, for 3 hr in the presence of diethylenetriaminepentaacetic acid (DTPA, 100 mg/L), at 80° C. The pH was maintained at 7 using ammonium hydroxide. The product was diafiltered as above with 6 vol. water containing 0.5% (wt/vol) SDS and 0.25% (wt/vol) Hypermer CG-6 followed by 6 vol. pure water. The particles were collected by centrifugation and resuspended in water at a concentration of 13% wt/wt. This PHA suspension, which had a median particle size of 3.9 μm and a crystallinity index of 100%, was used as the starting material in the process of producing a suspension of amorphous polymeric particles.
- The PHA suspension then was processed four times through a Microfluidizer M110EH (Microfluidics International, Newton, Mass.) at an operating pressure of 15,000 psi. The resulting suspension had a crystallinity index of 100% and a median particle size of 0.50 μm. The melting temperature of the crystalline polymer was determined to be 169° C.
- A portion of suspension (5 mL) was charged into a pressure-rate glass tube (Ace Glass), fitted with a magnetic stir bar, and then immersed for 5 min. in a silicone oil bath at 190° C. The tube then was removed and cooled down to room temperature. The product was a suspension of amorphous particles (0% crystallinity index by FTIR) with a median particle size of 0.53 μm. Gel permeation chromatography in chloroform showed that the molecular weight of the PHA remained ca. 300 kDa, which is similar to the molecular weight before the thermal treatment. Importantly, thermal treatment of 2.5 min. or less was insufficient to melt the crystalline PHA particles under the above conditions, while treatment of 10 min. duration caused most of the PHA to congeal into a solid mass.
- The thermal treatment was repeated using a suspension of crystalline PHA in water at 30% (wt/wt) solids, rather than 13% (wt/wt). The resulting product again was a suspension including amorphous PHA particles.
- Cells ofRalstonia eutrophus NCIMB 40124 were fermented to high density on a mixture of glucose and valeric acid under conditions of phosphorus limitation. The cells contained 32% PHA (cell dry weight basis) which was a PHBV copolymer with a monomer ratio 75:25 HB/HV. The PHA was isolated as in Example 1, except that following peroxide treatment, the PHA was isolated by centrifugation and resuspension in water to give a polymer slurry of 6% solids (wt/wt). At this stage, the PHA had a crystallinity index of approximately 70%. The slurry was then processed four times at 20,000 psi through a Microfluidizer M110EH to reduce the particle size and then immersed for 5 min. in a sealed tube in a 200° C. oil bath. The resulting product was a suspension of amorphous PHA (0% crystallinity index by FTIR) with a median particle size of 0.73 μm.
- A continuous flow apparatus as illustrated in FIG. 1 was used to form a suspension of amorphous polymer particles. The apparatus included an electronic diaphragm metering pump (Pulsatron E series, 250 psi rated, maximum flow rate 0.79 L/hr), a heat exchanger (inlet ⅜″ O.D.×12″ stainless pipe; outlet ⅛″ O.D.×12″ copper pipe), a heated zone (⅛″ O.D.×{fraction (1/16)}| I.D. copper pipe, four turns of ca. 4″ diameter, immersed in a thermostatically controlled oil (Dow Corning 550 silicone) bath), and a pressure regulating valve (Swagelok, 50-350 psi adjustable). The apparatus also was equipped with a pressure gauge and two thermocouple-type electronic thermometers.
- The oil bath was pre-heated to 175° C. and the apparatus was operated on a pure water feed stream for 15 min to purge air bubbles and approach thermal equilibrium. Fluid pressure was sufficient to prevent boiling of the water. After 15 min., the feed was changed to a PHA suspension (PHB-co-8%HV from Example 1 above, 13% wt/wt solids, ca. 0.5 μm median particle size, 100% crystallinity index, supplemented with 1% wt/vol potassium oleate). A flow rate of 16.5 mL/min was achieved at a pressure of 220-230 psi, which was sufficient to prevent boiling of the suspension. At this flow rate, the residence time of the suspension within the heated zone was approximately nine seconds. The temperature of the suspension leaving the heated zone was measured at 176° C., while the suspension leaving the outlet of the heat exchanger had a temperature of 66° C. The product suspension contained 13% (wt/wt) solids with 0% crystallinity index by FTIR. The optical microscope showed a submicron suspension of spherical particles.
- The procedures described in Example 3 above were repeated using a suspension including crystalline PHB particles (7.5% wt./wt. solids, 0.61 μm median particle size, crystallinity index 50%), obtained from fermentation ofRalstonia eutropha on glucose. The heating bath of the continuous flow apparatus was maintained at 197° C. The suspension has a temperature of 180° C. leaving the heated zone, while the suspension leaving the outlet of the heat exchanger had a temperature of 61° C. The discharged product included amorphous PHB particles (0.83 μm median particle size, 0% crystallinity index).
- Modifications and variations of the present invention will be obvious to those of skill in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the following claims.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/843,556 US6323276B2 (en) | 1998-06-09 | 2001-04-26 | Methods and apparatus for the production of amorphous polymer suspensions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8856598P | 1998-06-09 | 1998-06-09 | |
US09/328,783 US6228934B1 (en) | 1998-06-09 | 1999-06-09 | Methods and apparatus for the production of amorphous polymer suspensions |
US09/843,556 US6323276B2 (en) | 1998-06-09 | 2001-04-26 | Methods and apparatus for the production of amorphous polymer suspensions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/328,783 Division US6228934B1 (en) | 1998-06-09 | 1999-06-09 | Methods and apparatus for the production of amorphous polymer suspensions |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010023274A1 true US20010023274A1 (en) | 2001-09-20 |
US6323276B2 US6323276B2 (en) | 2001-11-27 |
Family
ID=22212117
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/328,783 Expired - Lifetime US6228934B1 (en) | 1998-06-09 | 1999-06-09 | Methods and apparatus for the production of amorphous polymer suspensions |
US09/843,586 Expired - Fee Related US6605262B2 (en) | 1998-06-09 | 2001-04-26 | Methods and apparatus for the production of amorphous polymer suspensions |
US09/843,556 Expired - Fee Related US6323276B2 (en) | 1998-06-09 | 2001-04-26 | Methods and apparatus for the production of amorphous polymer suspensions |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/328,783 Expired - Lifetime US6228934B1 (en) | 1998-06-09 | 1999-06-09 | Methods and apparatus for the production of amorphous polymer suspensions |
US09/843,586 Expired - Fee Related US6605262B2 (en) | 1998-06-09 | 2001-04-26 | Methods and apparatus for the production of amorphous polymer suspensions |
Country Status (9)
Country | Link |
---|---|
US (3) | US6228934B1 (en) |
EP (1) | EP1086164B1 (en) |
JP (1) | JP4368525B2 (en) |
AT (1) | ATE336537T1 (en) |
AU (1) | AU746769B2 (en) |
CA (1) | CA2333005A1 (en) |
DE (1) | DE69932818T2 (en) |
MX (1) | MXPA00011963A (en) |
WO (1) | WO1999064498A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
CN100339441C (en) | 2001-11-15 | 2007-09-26 | 生物材料公司 | Method for preparing gels |
US6699963B2 (en) | 2002-03-18 | 2004-03-02 | The Procter & Gamble Company | Grinding process for plastic material and compositions therefrom |
WO2004013204A2 (en) * | 2002-08-06 | 2004-02-12 | Metabolix Inc. | Polymer extraction methods |
CN1308395C (en) | 2002-11-08 | 2007-04-04 | 株式会社钟化 | Aqueous dispersion of biodegradable polyester and method for production thereof |
WO2004067756A1 (en) * | 2003-01-29 | 2004-08-12 | Biomatera Inc. | Method for controlling molecular weight and distribution of biopolymers |
ATE377060T1 (en) * | 2003-02-21 | 2007-11-15 | Metabolix Inc | PHA ADHESIVES |
US7781539B2 (en) * | 2003-02-21 | 2010-08-24 | Metabolix Inc. | PHA blends |
JP4201626B2 (en) * | 2003-03-14 | 2008-12-24 | 株式会社日本触媒 | Coating composition for heat drying |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
FR2859729B1 (en) * | 2003-09-12 | 2006-02-24 | Roquette Freres | AQUEOUS DISPERSIONS OF AT LEAST ONE BIODEGRADABLE POLYMER |
US9045595B2 (en) * | 2003-11-28 | 2015-06-02 | Phb Industrial S.A. | Process for recovering polyhydroxialkanoates (“PHAs”) from cellular biomass |
WO2005066256A1 (en) * | 2003-12-30 | 2005-07-21 | Metabolix, Inc. | Nucleating agents |
US7118897B2 (en) * | 2004-09-15 | 2006-10-10 | The Procter & Gamble Company | Process for the extraction of polyhydroxyalkanoates from biomass |
EP1813641B1 (en) * | 2006-01-30 | 2016-12-14 | Imec | A method for improving mechanical properties of polymer particles and its applications |
ES2624527T3 (en) | 2008-12-09 | 2017-07-14 | Kaneka Corporation | Process for producing poly-3-hydroxyalkanoate and agglomerate of poly-3-hydroxyalkanoate |
US20110300592A1 (en) | 2008-12-09 | 2011-12-08 | Kaneka Corporation | Method for producing poly-3-hydroxyalkanoic acid |
WO2011024023A1 (en) * | 2009-08-31 | 2011-03-03 | Ocv Intellectual Capital, Llc | Process for preparing aqueous emulsions of biodegradable polyesters |
ES2722748T3 (en) | 2011-04-29 | 2019-08-16 | Cj Cheiljedang Corp | Procedure for the production of latex by emulsification by fusion |
US9540661B2 (en) | 2012-07-09 | 2017-01-10 | Basf Se | Method for the complete anaerobic digestion of polymer mixtures |
WO2014009176A1 (en) | 2012-07-10 | 2014-01-16 | Basf Se | Method for complete anaerobic degradation of polymer mixtures |
US9475930B2 (en) | 2012-08-17 | 2016-10-25 | Metabolix, Inc. | Biobased rubber modifiers for polymer blends |
WO2014194220A1 (en) | 2013-05-30 | 2014-12-04 | Metabolix, Inc. | Recyclate blends |
CN106459544B (en) | 2014-03-27 | 2021-10-01 | Cj 第一制糖株式会社 | Highly filled polymer systems |
EP3608415A4 (en) | 2017-04-05 | 2021-01-13 | Kaneka Corporation | Polyhydroxyalkanoate particles and aqueous dispersion of same |
US11459521B2 (en) | 2018-06-05 | 2022-10-04 | Afton Chemical Coporation | Lubricant composition and dispersants therefor having a beneficial effect on oxidation stability |
US11078328B1 (en) * | 2020-10-30 | 2021-08-03 | Robert Whitehouse | Sequestered amorphous polyhydroxyalkanoate polymer (SAPP) material derived from cellular biomass and production thereof |
FR3137916A1 (en) * | 2022-07-13 | 2024-01-19 | Centre National De La Recherche Scientifique | Process for preparing poly-β-hydroxyalkanoate film |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB503827A (en) | 1936-07-07 | 1939-04-11 | Kodak Ltd | Process and materials for colour photography |
US3906059A (en) * | 1972-07-26 | 1975-09-16 | Tokuyama Soda Kk | Process for preparing vinyl chloride polymer composition having improved impact strength and processability |
JPS51135990A (en) * | 1975-05-20 | 1976-11-25 | Shin Etsu Chem Co Ltd | Method of removing residual monomers f rom polyvinylchloride slurries |
US4200734A (en) * | 1977-11-21 | 1980-04-29 | Diamond Shamrock Corporation | Process for polymerization of polyvinyl chloride and VCM monomer removal |
EP0145233B2 (en) | 1983-11-23 | 1991-11-06 | Imperial Chemical Industries Plc | Separation processfor a 3-hydroxybutyrate polymer |
JPS61215631A (en) | 1985-03-20 | 1986-09-25 | Japan Styrene Paper Co Ltd | Propylene random copolymer resin particle and its production |
US5451456A (en) | 1990-02-21 | 1995-09-19 | Pulp And Paper Research Institute Of Canada | Latex of poly-β-hydroxyalkanoates for treating fiber constructs and coating paper |
US5599891A (en) | 1992-09-28 | 1997-02-04 | Zeneca Limited | Polymer composition |
NL9401037A (en) | 1994-06-23 | 1996-02-01 | Soonn Stichting Onderzoek En O | Process for preparing a biodegradable polyhydroxyalkanoate coating using an aqueous dispersion of polyhydroxyalkanoate. |
GB2291648B (en) | 1994-07-25 | 1998-11-25 | Ici Plc | Aqueous coating composition giving coatings having improved early hardness and tack-resistance |
AU3188295A (en) * | 1994-08-18 | 1996-03-14 | Monsanto Company | Production of polymers of hydroxyalkanoic acids |
GB9416690D0 (en) | 1994-08-18 | 1994-10-12 | Zeneca Ltd | Process for the recovery of polyhydroxyalkanoic acid |
GB9424175D0 (en) | 1994-11-30 | 1995-01-18 | Cookson Group Plc | Process of metallizing phosphor screens |
JPH11500613A (en) | 1995-02-09 | 1999-01-19 | モンサント・カンパニー | Latex of polyhydroxyalkanoate |
US5891936A (en) * | 1995-02-16 | 1999-04-06 | Monsanto Company | Production of a polymer composition |
DE19530132C2 (en) | 1995-08-16 | 1998-07-16 | Max Planck Gesellschaft | Process for the purification, stabilization or isolation of nucleic acids from biological materials |
HU222563B1 (en) | 1995-08-21 | 2003-08-28 | The Procter & Gamble Co. | Solvent extraction of polyhydroxyalkanoates from biomass facilitated by the use of a marginal nonsolvent for pha |
US6083729A (en) | 1995-10-26 | 2000-07-04 | Metabolix, Inc. | Methods for isolating polyhydroxyalkanoates from plants |
AU1685197A (en) | 1995-12-08 | 1997-06-27 | University Of Alabama At Birmingham, The | Method and apparatus for cooling crystals |
-
1999
- 1999-06-09 EP EP99927369A patent/EP1086164B1/en not_active Expired - Lifetime
- 1999-06-09 CA CA002333005A patent/CA2333005A1/en not_active Abandoned
- 1999-06-09 US US09/328,783 patent/US6228934B1/en not_active Expired - Lifetime
- 1999-06-09 JP JP2000553499A patent/JP4368525B2/en not_active Expired - Lifetime
- 1999-06-09 AU AU44293/99A patent/AU746769B2/en not_active Ceased
- 1999-06-09 DE DE69932818T patent/DE69932818T2/en not_active Expired - Lifetime
- 1999-06-09 AT AT99927369T patent/ATE336537T1/en not_active IP Right Cessation
- 1999-06-09 WO PCT/US1999/012932 patent/WO1999064498A1/en active IP Right Grant
- 1999-06-09 MX MXPA00011963A patent/MXPA00011963A/en not_active IP Right Cessation
-
2001
- 2001-04-26 US US09/843,586 patent/US6605262B2/en not_active Expired - Fee Related
- 2001-04-26 US US09/843,556 patent/US6323276B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1999064498A1 (en) | 1999-12-16 |
US6228934B1 (en) | 2001-05-08 |
CA2333005A1 (en) | 1999-12-16 |
US6323276B2 (en) | 2001-11-27 |
EP1086164B1 (en) | 2006-08-16 |
JP4368525B2 (en) | 2009-11-18 |
US20010024631A1 (en) | 2001-09-27 |
AU746769B2 (en) | 2002-05-02 |
US6605262B2 (en) | 2003-08-12 |
EP1086164A1 (en) | 2001-03-28 |
ATE336537T1 (en) | 2006-09-15 |
MXPA00011963A (en) | 2003-04-22 |
JP2002517582A (en) | 2002-06-18 |
AU4429399A (en) | 1999-12-30 |
DE69932818D1 (en) | 2006-09-28 |
DE69932818T2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6605262B2 (en) | Methods and apparatus for the production of amorphous polymer suspensions | |
CN109843985B (en) | Method for producing polyhydroxyalkanoate | |
EP0091224B1 (en) | Process for producing a shaped article of beta-hydroxybutyrate polymer | |
JP5635465B2 (en) | Process for producing polyester latex with improved hydrolytic stability | |
WO2021251049A1 (en) | Method for producing polyhydroxyalkanoic acid and use of same | |
US5952460A (en) | Process of recovering polymers of hydroxyalkanoic acids | |
JP7209434B2 (en) | Method for producing polyhydroxyalkanoic acid and use thereof | |
EP0809669B1 (en) | Production of a polymer composition | |
JP3773526B2 (en) | Method for increasing polymer particle size | |
US20230102977A1 (en) | Method for producing polyhydroxyalkanoate and use of same | |
JP2000502375A (en) | Dispersion system of polyhydroxyalkanoate in water | |
US11104761B1 (en) | Sequestered amorphous polyhydroxyalkanoate polymer (SAPP) material derived from cellular biomass and production thereof | |
US11078328B1 (en) | Sequestered amorphous polyhydroxyalkanoate polymer (SAPP) material derived from cellular biomass and production thereof | |
WO2021161732A1 (en) | Method for producing polyhydroxyalkanoate and use of same | |
JP2023178063A (en) | Method for producing polyhydroxyalkanoic acid and use thereof | |
EP4237466A1 (en) | Sequestered amorphous polyhydroxyalkanoate polymer (sapp) material derived from cellular biomass and production thereof | |
WO2024003698A1 (en) | Process for recovering and purifying polyhydroxyalkanoates from a fermentation broth | |
EP0866830A1 (en) | Polyester particles | |
JPS58217520A (en) | Separation of polymer from 3-hydroxybutylate polymer solution | |
MXPA98004818A (en) | Polyestic particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REFU | Refund |
Free format text: REFUND - SURCHARGE, PETITION TO ACCEPT PYMT AFTER EXP, UNINTENTIONAL (ORIGINAL EVENT CODE: R2551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: METABOLIX, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HOROWITZ, DANIEL;GERNGROSS, TILLMAN U.;REEL/FRAME:016446/0838;SIGNING DATES FROM 19990623 TO 19990719 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131127 |